arrow
A

Andrew Artz

city of hope national medical center
H指数:55
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CAR T‑Cell Therapy as a Bridging Strategy to Second Transplant in Relapsed B‑Cell ALL

CAR T细胞疗法作为B细胞急性淋巴细胞白血病复发患者二次移植的桥梁策略

2026-10-030
PRE
CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission

CAR T细胞疗法作为B-ALL老年患者首次完全缓解期的确定性巩固治疗

2026-06-260
OA
The Influence of Race/Ethnicity and Social Vulnerability on Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant in Older (≥60 Years) Adults

种族/族裔和社会脆弱性对老年(≥60岁)异基因造血细胞移植后非复发死亡率的影响

2026-05-280
PRE
Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT)

单中心评估一种复合风险预测模型,用于预测异基因造血细胞移植(HCT)后的非复发死亡率。

2026-04-080
PRE
American Society of Hematology 2026 guidelines for treating newly diagnosed acute myeloid leukemia in older adults

Sekeres, M.A.; Mattison, R.J.; Artz, A.S.; Baer, M.R.; Chua, C.C.; Demichelis-Gomez, R.; Egan, P.C.; Fletcher, L.; Foucar, C.E.; Garcia, J.S.; et al. 美国血液学会2025年关于老年新诊断急性髓系白血病治疗的指南。Blood Adv. 2025. [Google Scholar] [CrossRef]

2026-03-130
OAAI
Non-Myeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS

非清髓性预处理联合抗-CD117抗体Briquilimab在具有高风险AML和MDS的老年患者中的应用

Blood
IF23.1
2026-03-090
PRE
Conventional Therapy vs HMA or LDAC ± Venetoclax in Older Adults With AML: Systematic Review and Meta-analysis

常规疗法与HMA或LDAC±Venetoclax在老年AML患者中的应用:系统评价与Meta分析

2026-02-130
OAAI
CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study

CHARM是老年患者异基因移植后预测老年病发病率和毒性的指标:BMT CTN 1704研究

2025-11-240
OAAI
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis

异基因造血干细胞移植(allo-HCT)在采用氟达拉滨/美法仑(Fludarabine/Melphalan)预处理和他克莫司/西罗莫司(Tacrolimus/Sirolimus)移植物抗宿主病(GVHD)预防方案的急性髓系白血病(AML)中的长期生存结局。

2025-11-180
OAAI
Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis

异基因造血细胞移植治疗骨髓纤维化受者中中性粒细胞植入期间的肺部表现

2025-09-240
OA
Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplant in Patients With IDH-2 Mutated AML

在IDH-2突变急性髓系白血病异基因造血细胞移植后使用enasidenib维持治疗的试验

2025-09-190
PRE
The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia

靶向治疗和免疫疗法在TP53突变急性淋巴细胞白血病患者中的疗效

2025-09-010
PRE
Assessing Cognitive Function in Transplantation and CAR-T Recipients: Expert Recommendations from the Survivorship, Aging and Biobehavioral Special Interest Groups of ASTCT

评估移植和CAR-T接受者的认知功能:ASTCT生存率、老龄化和生物行为特别兴趣小组的专家建议

2025-07-010
PRE
Outcomes After Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment

基于美法仑的减低强度异基因造血细胞移植在肾功能不全患者中的结局

2025-07-010
PRE
Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect

基于美法仑的预处理联合移植后环磷酰胺用于外周血干细胞移植:供者效应

2025-02-270
OA
Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxis
2025-02-200
OAAI
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines

美国老年评估实践:针对接受造血细胞移植或嵌合抗原受体T细胞治疗的老年人——移植与细胞治疗学会老年特别兴趣小组与实践指南委员会医师调查

2025-02-010
PRE
Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704

新型异基因移植受者健康评估风险模型:BMT-CTN 1704

2025-01-010
OAAI